We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride Tablets

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00913822
First Posted: June 4, 2009
Last Update Posted: March 28, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Sandoz
  Purpose
To demonstrate the relative bioavailability of Desipramine Hydrochloride tablets.

Condition Intervention Phase
Depression Drug: Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories) Drug: Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.) Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Bioavailability of Desipramine Hydrochloride Tablets

Resource links provided by NLM:


Further study details as provided by Sandoz:

Primary Outcome Measures:
  • Bioequivalence based on AUC and Cmax [ Time Frame: 22 days ]

Enrollment: 36
Study Start Date: December 1987
Study Completion Date: December 1987
Primary Completion Date: December 1987 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)
Drug: Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)
Active Comparator: 2
Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)
Drug: Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

  • Positive test results for HIV or hepatitis B or C.
  • Treatment for drug or alcohol dependence.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00913822


Sponsors and Collaborators
Sandoz
Investigators
Principal Investigator: Jules Kann, M.D. University of Pittsburgh
  More Information

Responsible Party: Eric Mittleberg, Ph.D, VP of Product Development, Sandoz Inc.
ClinicalTrials.gov Identifier: NCT00913822     History of Changes
Other Study ID Numbers: 870609D
First Submitted: June 2, 2009
First Posted: June 4, 2009
Last Update Posted: March 28, 2017
Last Verified: June 2009

Keywords provided by Sandoz:
Antidepressant

Additional relevant MeSH terms:
Desipramine
Antidepressive Agents, Tricyclic
Antidepressive Agents
Psychotropic Drugs
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Adrenergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs